Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. 2004

Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
Department of Virology, INSERM EMI 0214, Pitié-Salpêtrière Hospital, Paris, France. marc.wirden@psl.ap-hop-paris.fr

The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016016 Proportional Hazards Models Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time. Cox Model,Cox Proportional Hazards Model,Hazard Model,Hazards Model,Hazards Models,Models, Proportional Hazards,Proportional Hazard Model,Proportional Hazards Model,Cox Models,Cox Proportional Hazards Models,Hazard Models,Proportional Hazard Models,Hazard Model, Proportional,Hazard Models, Proportional,Hazards Model, Proportional,Hazards Models, Proportional,Model, Cox,Model, Hazard,Model, Hazards,Model, Proportional Hazard,Model, Proportional Hazards,Models, Cox,Models, Hazard,Models, Hazards,Models, Proportional Hazard
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
January 2013, Advances in pharmacology (San Diego, Calif.),
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
August 2013, AIDS research and human retroviruses,
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
July 2009, AIDS (London, England),
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
September 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
May 2010, Journal of virology,
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
January 2004, BMJ (Clinical research ed.),
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
January 1996, Biochemistry,
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
February 2001, Enfermedades infecciosas y microbiologia clinica,
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
January 2009, Antiviral therapy,
Marc Wirden, and Constance Delaugerre, and Anne Genevieve Marcelin, and Nadine Ktorza, and Hocine Ait Mohand, and Stephanie Dominguez, and Luminita Schneider, and Jade Ghosn, and Michele Pauchard, and Dominique Costagliola, and Christine Katlama, and Vincent Calvez
August 2006, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!